Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by Caris Molecular Intelligence™, this study represents the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Colorectal cancer is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients.
“This comprehensive analysis of more than 7,000 patient cases illustrates that treatment of this cancer as one single disease is a flawed approach. The variety of mutations identified also point the way to new combinations of therapies and protein targets that can help direct future treatments,†said Fadi Braiteh, M.D. and co-author on the study. “We are definitely moving from treating colon cancer as one disease to treating it as 20 to 30 different diseases. This research also highlights the feasibility of tumor profiling for colorectal cancer in the community setting, as well as establishes a high bar for standard of care for these patients.â€